BiotechTube

MK0524

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Allergies

Conditions

Seasonal Allergies

Trial Timeline

Jul 1, 2003 → Oct 1, 2003

NCT ID
NCT00533208

About MK0524

MK0524 is a phase 2 stage product being developed by Merck for Seasonal Allergies. The current trial status is completed. This product is registered under clinical trial identifier NCT00533208. Target conditions include Seasonal Allergies.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00533208Phase 2Completed

Competing Products

20 competing products in Seasonal Allergies

See all competitors
ProductCompanyStageHype Score
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
52
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
33
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + PlaceboAstraZenecaPhase 2
52
budesonide + PlaceboAstraZenecaPhase 2
52
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide Nasal SprayAstraZenecaPhase 3
77
Budesonide + Fluticasone propionate + PlaceboAstraZenecaPhase 3
77
Ciclesonide + Ciclesonide PlaceboAstraZenecaPhase 3
77
loratadineMerckPre-clinical
23
loratadine; montelukastMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85